Table 4.
WT |
HCAR1 KO |
|||
---|---|---|---|---|
Frequency (%) | ncells, nexp | Frequency (%) | ncells, nexp | |
GABABR/HCAR1 | ||||
3,5-DHBAa | 32.3 ± 6.9 | 37, 4 | ||
→ + baclofen | 2.6 ± 3.3* | |||
Baclofen | 13.9 ± 0.8 | 12, 3 | 53.2 ± 3.4 | 35, 4 |
→ + 3,5-DHBA | 43.6 ± 5.5* | 51.7 ± 4.5 n.s. | ||
α2AR/HCAR1 | ||||
3,5-DHBA | 48.4 ± 8.9 | 44, 4 | ||
→ + Guanfacine | 8.4 ± 3.3* | |||
Guanfacine | 24.2 ± 2.8 | 36, 4 | 26.8 ± 8.4 | 29, 4 |
→ + 3,5-DHBA | 54.2 ± 4.1* | 27.2 ± 8.2n.s. |
Data are expressed as the percentage of the frequency observed in baseline conditions and as the mean ± SEM. n.s., not significant ANOVA, Bonferroni correction, for n cells from n experiments. Statistical significance is indicated for comparisons between the two displayed conditions.
aConcentrations used: 1 mm 3,5-DHBA, 0.5 μm baclofen, and 10 μm guanfacine.
*p < 0.05.